secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001753926-25-000792
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical Q1 net loss $6.3M; secures $3M private placement; LIBERATE-1 data mid-2025
--------------------------------------------------------------------------------

- Q1 net loss of $6.3M (vs $6.0M prior year); cash, equivalents & restricted cash $14.3M as of March 31.
- Announced $3.0M private placement with Chairman Gregg Williams entity at $1.03/share (2.9M shares).
- LIBERATE-1 Phase 1 study on track; all NPM-115 (exenatide) implant insertions successful; top-line results mid-2025.
- Promising preclinical data for NPM-139 semaglutide implant for chronic weight management in obese/overweight.
- Plans to spin off Cortigent brain implant division as an independent publicly traded company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625000792/0001753926-25-000792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625000792/vani-20250512.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-000792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer